{
    "clinical_study": {
        "@rank": "161636", 
        "acronym": "NIH fracture", 
        "arm_group": [
            {
                "arm_group_label": "500 with BP treatment", 
                "description": "patients will undergo lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)"
            }, 
            {
                "arm_group_label": "500 without BP treatment", 
                "description": "patients will undergo lab tests, X-ray, bone scan or MRI, as needed"
            }
        ], 
        "biospec_descr": {
            "textblock": "Bone & serum to be retained per institutional guidelines and clinical practice"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The purpose of this protocol is to determine the risk of atypical femoral shaft (thigh bone)\n      fractures after long term fracture prevention therapy with a class of drugs called\n      \"bisphosphonates\", colloquially referred to as Alendronate, risedronate, Ibandronate, and\n      Zoledronate.\n\n      In addition, the study is designed to find out which patient is most likely to develop this\n      potential life changing complication and why. Finally, the results of this study will help\n      clinicians to better understand the reason and thus tailor patient specific treatments\u2026i.e.,\n      \"the right treatment for the right patient for right duration.\""
        }, 
        "brief_title": "Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy", 
        "completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Osteoporosis", 
            "Atypical Femoral Fractures", 
            "Prodromal Bone Deterioration"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Femoral Fractures", 
                "Fractures, Bone", 
                "Osteoporosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  women with a diagnosis of osteopenia or osteoporosis as defined by Bone Mineral\n             density (BMD)\n\n          -  patient treated with BPs for >5 years\n\n          -  patients treated with non-BP anti-fracture medications such as...\n\n          -  estrogens, raloxifene, calcitonin\n\n          -  treatment naive patients\n\n        Exclusion Criteria:\n\n          -  all men regardless of BMD result\n\n          -  patients with obvious traumatic AFF\n\n          -  patients with normal BMD (better than -1.0 T-score at spine or proximal hip)\n\n          -  unable to take tetracycline\n\n          -  previous use of teriparatide\n\n          -  known allergies to the following:\n\n          -  tetracycline antibiotics\n\n          -  meperidine\n\n          -  midazolam"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients will be found within the Henry Ford Health System Division of Endocrinology,\n        Diabetes, Bone & Mineral Disorders"
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02155595", 
            "org_study_id": "1R01AR062103-01A1"
        }, 
        "intervention": [
            {
                "arm_group_label": "500 without BP treatment", 
                "description": "lab tests, X-ray, bone scan or MRI, as needed", 
                "intervention_name": "500 without BP treatment", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "500 with BP treatment", 
                "description": "lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)", 
                "intervention_name": "500 with BP treatment", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Diphosphonates"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "contact": {
                "email": "srao1@hfhs.org", 
                "last_name": "Sudhaker D. Rao, M.B;B.S.", 
                "phone": "313-971-4984"
            }, 
            "facility": {
                "address": {
                    "city": "Detroit", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48202"
                }, 
                "name": "Henry Ford Medical Center, New Center One"
            }, 
            "investigator": {
                "last_name": "Sudhaker D. Rao, M.B;B.S.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy", 
        "other_outcome": {
            "description": "Determine the prevalence of osteocyte lacunae.  In BP treated patients with Severely Suppressed Bone Turnover (SSBT), PBD, or AFF, or with none of these complications, determine the prevalence of osteocyte lacunae in osteonal and interstitial iliac cortical bone", 
            "measure": "Osteocyte lacunae", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "overall_contact": {
            "email": "srao1@hfhs.org", 
            "last_name": "Sudhaker D. Rao, M.B;B.S.", 
            "phone": "313-971-4984"
        }, 
        "overall_official": {
            "affiliation": "Henry Ford Health System", 
            "last_name": "Sudhaker D. Rao, M.B;B.S.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the prevalence of PBD and/or Atypical Femoral Fractures (AFF) in patients with post-menopausal or glucocorticoid related osteoporosis, either treated with bisphosphonate (BP) for more than 2 years or never treated with a BP", 
            "measure": "Prodromal bone deterioration (PBD)", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02155595"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Henry Ford Health System", 
            "investigator_full_name": "Sudhaker D Rao, MD", 
            "investigator_title": "Senior staff physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Refine diagnostic criteria for the diagnosis of PBD", 
            "measure": "Diagnosis of PBD", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "source": "Henry Ford Health System", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Henry Ford Health System", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}